热门资讯> 正文
周六报道，Olema Oncology报告了2025年ESCO上使用Palazestrant + Ribociclib治疗ER阳性、HER 2阴性转移性乳腺癌的15.5个月中位无进展生存期
2025-10-20 16:26
- 夏威夷电力实业(HE) 0
- 能源方案(ES) 0
- 奥驰亚(MO) 0
- Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups
- Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients
- In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors
- Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known profiles of each drug
- Data support the ongoing Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline advanced or metastatic breast cancer
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
